Location:
Berg Family Foundation Seminar Room, Level 6, Wallace Wurth Building, Kensington Campus
Contact for enquiries
Rata Joseph, +61 (2) 9385 0900 or recpt@kirby.unsw.edu.au
A catered lunch will be provided at 12:30pm. Please RSVP to recpt@kirby.unsw.edu.au by COB Friday 31 January.
Kirby Institute Seminar Series presents
 |
Honorary Professor Mark Sullivan Managing Director, Medicines Development for Global Health Mark Sullivan is the founder and managing director of the not-for-profit Medicines Development for Global Health. He has a pharmaceutical development and clinical research background, working for GSK in London and Gilead Sciences in California on the development of medicines for HIV and hepatitis. He has worked on 40 small molecule and biologic development programs at all stages, and led the capital raising and development of moxidectin for the treatment of onchocerciasis through FDA approval. Mark was 33rd on the 2019 Fast Company 100 Most Creative people, is the 2019 Australian of the Year for Victoria and is an Honorary Professor at the Kirby Institute. |
Abstract
January 30 2020 marked the first ever World Neglected Tropical Diseases Day, reminding us that just 2% of the total research and development spend is on neglected tropical diseases, which affect 33% of the global population. Medicines Development for Global Health was formed to address this inequity through development of new medicines and vaccines for diseases of poverty. In 2018, it became the first Australian company and the first not for profit company in history to register a novel medicine (moxidectin) with the US FDA, creating a new and sustainable model that is globally unique. The company is now running implementation clinical trials and planning for delivery to the field.